The papers are here for a closer look.
A title can sound impressive without answering your question. I find it helps to know what kind of source I’m opening: an experiment, a review or an FDA assessment.
Skin, copper and visible changes
The reviews bring studies together. The experiments ask narrower questions about creams or copper delivery.
- GHK wrinkle research and the delivery problem. Mortazavi and colleagues, BioImpacts, 2025. Reviews skin research and the difficulty of getting the ingredient through skin.
- GHK research on skin. Pickart and colleagues, BioMed Research International, 2015. Reports small cream studies, with some original reports in conference material or a book chapter.
- Copper-peptide skincare after laser treatment. Miller and colleagues, Archives of Facial Plastic Surgery, 2006. The groups had no statistically clear difference in measured redness or wrinkle improvement, though participants using copper peptides felt more satisfied.
- Copper entering donated human skin. Hostynek and colleagues, Inflammation Research, 2011. Copper entered and stayed in lab skin samples; the study didn't measure visible skin changes.
The next papers move from skin to repair.
BPC-157 and the blend question
None of these papers tests GLOW in a controlled human trial.
- Healing of cut rat Achilles tendons. Staresinic and colleagues, Journal of Orthopaedic Research, 2003. Better tendon healing measures in rats, without a human recovery result.
- Intravenous BPC-157 safety pilot. Alternative Therapies in Health and Medicine, 2025. Two adults, no observed side effects, and no test of injury healing.
- Review of BPC-157 for muscle, bone and tendon healing. McGuire and colleagues, Current Reviews in Musculoskeletal Medicine, 2025. Mostly animal research, with limited human evidence.
- BPC-157 and blood-vessel growth. Hsieh and colleagues, Journal of Molecular Medicine, 2017. Lab and animal work, rather than a test of cancer risk in people.
- Approved and unapproved peptide therapies. Mendias and Awan, Sports Medicine, 2026. Reviews relevant ingredients and scarce rigorous human safety data.
FDA has its own assessments and safety questions.
FDA status and safety concerns
A withdrawn request isn't approval. A staff assessment isn't a final FDA listing decision.
- FDA safety concerns and withdrawn nominations. Page current as of April 22, 2026. Lists BPC-157, TB-500 and injectable GHK-Cu as nominated but withdrawn, with safety concerns still stated.
- FDA assessment of BPC-157. July 2026 committee material. Reviews the limited human evidence and gaps in safety information.
- FDA assessment of TB-500. July 2026 committee material. Separates the fragment from thymosin beta-4 and discusses missing human research and testing gaps.